Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Sarepta Falls on Plans for Early 2014 Drug Filing

By Pharmaceutical Processing | July 24, 2013

NEW YORK (AP) — Shares of Sarepta Therapeutics Inc. fell Wednesday after the company said it will file for marketing approval of its most advanced experimental drug in the first half of 2014.

Sarepta is studying eteplirsen as a treatment for Duchenne muscular dystrophy, a rare and fatal genetic disease that causes increasing muscle weakness and affects one of every 3,500 boys worldwide. The company plans to file for marketing approval of eteplirsen by the end of June 2014, which means the drug could receive Food and Drug Administration clearance in late 2014 or early 2015. A standard FDA review takes 10 months.

Its shares lost $8.46, or 18.2 percent, to $37.97 in afternoon trading. The price of Sarepta shares has climbed sixfold over the last year and is currently at its highest level in seven years.

Deutsche Bank analyst Robyn Karnauskas downgraded Sarepta shares to “Hold” from “Buy,” saying the company is making progress but the shares have been strong. Karnauskas said in a research note the stock has advanced in the last few months because Wall Street expects accelerated approval for eteplirsen, but it’s not clear that Sarepta will be able to win a quicker approval. The analyst kept a $45 price target on the stock.

The Cambridge, Mass., company does not have any drugs on the market.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE